Traditional generics player Glenmark Pharmaceuticals Limited has championed the company’s first innovative product approval in EU markets with its Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray, which is to be sold through a combination of Glenmark’s internal sales force and licensing partner the Menarini Group.
The Indian firm is “concluding the final, national phase of its marketing approval application process,” to enable launch of the...



